⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27469533 | 0.96 | — | — | |
| SCHEMBL1752289 | 0.81 | — | — | |
| SCHEMBL5944718 | 0.75 | — | — | |
| SCHEMBL5944764 | 0.67 | — | — | |
| SCHEMBL25433869 | 0.58 | — | — | |
| SCHEMBL2056746 | 0.55 | — | — | |
| SCHEMBL23234265 | 0.55 | MEN1 (0.41) | — | |
| SCHEMBL2212439 | 0.55 | — | — | |
| SCHEMBL1261339 | 0.55 | — | — | |
| Hydrogen Peroxide SCHEMBL28137596 | 0.54 | TP53 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110267958-A | Process for preparing pyrazolo [1,5-a ] pyrimidines and salts thereof | 阿雷生物药品公司 | 2019-09-20 | — | — | CN | claimed |
| CN-109983006-A | Crystalline forms of lysyl oxidase-like 2 inhibitors and methods of making the same | 法玛克亚公司 | 2019-07-05 | — | — | CN | claimed |
| CN-109928952-A | A kind of lipoic acid disubstitution product and its application | 大连中信药业股份有限公司 | 2019-06-25 | — | — | CN | claimed |
| CN-104981467-B | Process for the preparation of l- (4- (4- (3, 4-dichloro-2-fluorophenylamino) -7-methoxyquinazolin-6-yloxy) piperidin-l-yl) prop-2-en-l-one | 韩美药品株式会社 | 2017-10-24 | — | — | CN | claimed |
| CN-106397256-A | Synthesis method of compound 3 (2-acetamido) -propionic acid for inhibiting melanin generation | 新钰生技股份有限公司 | 2017-02-15 | — | — | CN | claimed |
| CN-104004083-B | A kind of method synthesizing Arg34Lys26-(N-EPSILON-(N-ALPHA-Palmitoyl-L-GAMMA-glutamyl))-GLP-1[7-37] | 成都圣诺生物科技股份有限公司 | 2016-10-05 | — | — | CN | claimed |
| CN-105753844-A | Novel method for synthesizing dimethyl dicarbamate dihydrochloride compound | 江苏苏利精细化工股份有限公司 | 2016-07-13 | — | — | CN | claimed |
| CN-105601543-A | Complete synthesis method of natural product Nostosin B | JIANGXI SCIENCE & TECH NORMAL UNIV | 2016-05-25 | — | — | CN | claimed |
| CN-105056213-A | Glucose responsive supermolecule nanosphere, and preparation method and applications thereof | UNIV NANKAI | 2015-11-18 | — | — | CN | claimed |
| CN-101604607-A | Coating composition for interconnection part of electrode and comprise its plasma display | SAMSUNG SDI CO LTD (KR) | 2009-12-16 | — | — | CN | claimed |
| CN-115611925-A | HPK1 inhibitors and uses thereof | 轩竹生物科技股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| CN-108617166-B | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-05-17 | — | — | CN | disclosed |
| CN-113874079-A | Bridged tricyclic carbamoylpyridone compounds and pharmaceutical use thereof | 吉利德科学公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-106458964-B | The salt of halogen substituted heterocyclic compound | 宇部兴产株式会社 | 2019-11-22 | — | — | CN | disclosed |
| CN-1317011-A | Process for couping amino acids using bis-(trichloromethyl) carbonate | PEPTOR LTD (IL) | 2001-10-10 | — | — | CN | disclosed |
| CN-1259140-A | Treatment of insulin resistance with growth hormone secretagogues | PFIZER PROD INC (US) | 2000-07-05 | — | — | CN | disclosed |
| CN-1206422-A | Growth-hormone secretagogues | PFIZER (US) | 1999-01-27 | — | — | CN | disclosed |
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | disclosed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |